Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3503 | Saline Control Wiki | 1.00 |
| drug2252 | MSC Treatment Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this clinical trial is to determine the efficacy of Previfenon® (EGCG) to prevent COVID-19, enhance systemic immunity, and decrease the frequency and intensity of selected symptoms when used as pre-exposure chemoprophylaxis to SARS-CoV-2.
Description: A positive case or event of COVID-19 is defined as a patient with acute respiratory illness presenting fever (37.8º C); at least one of the following symptoms: odynophagia, cough, myalgia, or dyspnea; and a specific positive rtPCR test for SARS-CoV-2.
Measure: Event of clinical acute respiratory disease with a diagnosis of COVID-19 confirmed with rtPCR Time: The date for censoring a case will be defined as that date when the rtPCR test results positive minus 4 days, with the aim to calculate the time free of clinically defined COVID-19 infection over 40 to 70 days of interventionDescription: Rate of positive cases for IgM and IgG anti-SARS-CoV-2 measured by immunochromatographic test in treatment and placebo group at the end of the study
Measure: Rate of positive cases for IgM and IgG anti-SARS-CoV-2 Time: Positive cases in each two-week examination and to the end of the study over 40 to 70 days of interventionDescription: Rate of asymptomatic cases defined as a positive rtPCR for SARS-CoV-2 viral RNA but with no symptoms of COVID-19 in treatment and placebo group at the end of the study, and a composite outcome considering symptomatic and asymptomatic cases (i.e. all cases with positive rtPCR test)
Measure: Composite outcome considering symptomatic and asymptomatic cases with positive rtPCR test Time: Positive cases in each two-weeks examination and to the end of the study over 40 to 70 days of interventionDescription: Rate of hospitalizations due to any acute respiratory infection at the end of the study
Measure: Hospitalization due to any acute respiratory infection Time: Positive cases in each two-week examination visit and to the end of the study over 40 to 70 days of interventionDescription: Global frequency of events of upper and lower airway respiratory infections
Measure: Event of upper and lower airway respiratory infection Time: Positive cases in each two-week examination and to the end of the study over 40 to 70 days of interventionDescription: Registry of Visual Analogue Scale (VAS) in the log diary of every healthcare worker for the following selected symptoms: cough, muscle pain (myalgia); difficulty breathing (dyspnea); loss of smell (anosmia); loss of taste (ageusia); pain when swallowing (odynophagia, sore throat); and finally headache
Measure: Exploratory outcome: Frequency and intensity of selected symptoms for COVID-19 Time: Different VAS scores calculated each two-week examination visit over 40 to 70 days of interventionDescription: Elevation of liver enzymes over 5 times the normal value
Measure: Primary safety outcome: event of major hepatic harm Time: Cases accounted by liver profile lab test in each two-week examination visit over 40 to 70 days of intervention.Description: Elevation of liver enzymes over 5 times the normal value
Measure: Event of liver enzymes over 3 times the normal value Time: Cases accounted by liver profile lab test in each two-week examination visit over 40 to 70 days of interventionDescription: Any adverse event reported over the intervention period
Measure: Frequency of adverse events Time: Records of self-reported adverse effects on log dairy accounted in each examination visit over 40 to 70 days of interventionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports